Sprint Bioscience AB

As of June 30, 2026, Sprint Bioscience AB carries a market capitalization of 436.83M, placing it among publicly traded companies globally. Its enterprise value stands at 343.57M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Sprint Bioscience AB's next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, Sprint Bioscience AB has 105.52M shares outstanding.

As of June 30, 2026, Sprint Bioscience AB trades at a trailing price-to-earnings ratio of 5.77. The price-to-sales ratio is 3.14, and the price-to-book ratio stands at 4.85.

As of June 30, 2026, Sprint Bioscience AB trades at an EV/EBITDA multiple of 4.33 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.47 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 4.39 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Sprint Bioscience AB trades at an EV/FCF ratio of 4.73, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 343.57M versus a market cap of 436.83M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Sprint Bioscience AB maintains a current ratio of 7.09, meaning it holds 7.1x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Sprint Bioscience AB posted a return on equity (ROE) of 144.94, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 149.87 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 105.90, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 154.68, useful for judging operating efficiency across full business cycles. The company generates approximately 4.35M in revenue per employee across its workforce of 32.00, a quick read on workforce productivity versus industry peers.

As of the close on October 23, 2026, Sprint Bioscience AB's stock has gained approximately 371.43% over the past 52 weeks. The 50-day moving average sits at 3.25, while the 200-day moving average is 3.02.

Over the twelve months ended June 30, 2026, Sprint Bioscience AB generated 139.15M in revenue and converted that into 75.65M in net income, yielding earnings per share of 0.72. EBITDA reached 79.31M, while operating income came in at 78.23M.

These figures are as of June 30, 2026. Total book value stands at 90.08M, with working capital of 86.40M providing operational flexibility.

Sprint Bioscience AB produced 68.04M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -505,000.00 in capital expenditures, free cash flow totaled 67.53M - equivalent to 0.64 per share.

Over the twelve months ended June 30, 2026, Sprint Bioscience AB posted a gross margin of 94.71, reflecting its pricing power and cost economics. The operating margin of 56.22 and net profit margin of 54.37 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 15.46, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -0.03, meaning Sprint Bioscience AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Sprint Bioscience AB's most recent stock split took place on April 3, 2025 with a 771:784 split ratio.

As of June 30, 2026, Sprint Bioscience AB has an Altman Z-Score of 20.46, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.